AGM
ZNTL icon

Alpine Global Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Alpine Global Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-30,164
Closed -$48K – 209
2025
Q1 		$48K Buy
+30,164
New +$65K 0.01% 116

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

Alpine Global Management's ZNTL Position: Q2 2025 in Review

Alpine Global Management sold out of Zentalis Pharmaceuticals (ZNTL) in Q2 2025, closing a stake of 30,164 shares — an estimated $48K sold.

Alpine Global Management first reported a position in ZNTL in Q1 2025 and held it in 1 quarter. The position peaked at $48K in Q1 2025. 117 funds tracked by Wall St. Rank hold ZNTL as of Q2 2025.

  • Alpine Global Management reported no remaining Zentalis Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Alpine Global Management sold 30,164 Zentalis Pharmaceuticals shares in Q2 2025, an estimated $48K.
  • Alpine Global Management first reported a position in Zentalis Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Alpine Global Management's Zentalis Pharmaceuticals position peaked at $48K in Q1 2025.
  • 117 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2025.

Based on Alpine Global Management's 13F filing for Q2 2025, filed 14 Aug 2025.